ProBioGen has closed a Master Service Agreement with NextPoint and initiated development and GMP manufacturing of their lead antibody candidate.
ProBioGen is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.
We are proud NextPoint has selected us for this fast track CMC development and manufacturing of its unique antibody
ProBioGen's CHO.RiGHT cell line development including their latest DirectedLuck transposase and platform processes enables the development to provide a high-expressing stable cell line and a robust manufacturing process. Further, ProBioGen's proprietary cell culture medium makes manufacturing processes even more robust, with improved protein titers and cell growth behavior.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
"We are proud NextPoint has selected us for this fast track CMC development and manufacturing of its unique antibody that targets a novel immune checkpoint axis offering promise for hard-to-treat cancers. We are thrilled to support them with our expertise and technology to move this candidate towards the clinic," said Dr Gabriele Schneider, Chief Business Offer for ProBioGen.